Medicus AI Closes the First Tranche of its Series A Funding Round of €5 Million

MedicusMedicus AI GmbH announced the completion of the first tranche of its Series A funding round at €2.75 million, with the purview to close the second tranche of €2.25 million over the coming months.

Medicus works with diagnostic labs to deliver smart features and insights to doctors, in terms of smart testing and diagnosis support, and to patients, in the form of visual and interactive reports, powering continuous healthcare and coaching across all digital platforms.

"At Medicus, we believe that healthcare is in dire need of a user-experience overhaul and that people today are used to experiencing things in a much simpler and clearer fashion, yet healthcare is still complex and impenetrable. We believe this augmentation can unlock massive value that reverberates across the whole healthcare system," said Dr Baher al Hakim, CEO, Medicus.

The Series A funding round will further fuel the company's global expansion, as well as the development of the Medicus diagnostic lab and insurance products, across core markets and in new languages. To date, Medicus supports, German, French, English and Arabic, with Italian, Chinese, Portuguese and Spanish in the pipeline for 2019.

The diagnostic lab space, which makes up Medicus' current core client base, generates an estimated 20 billion reports annually worldwide. However, the industry operates in highly consolidated markets and struggle to differentiate themselves, maintain growthand introduce future-proof business models.

"Our proposition to diagnostic labs is simple. We empower labs to deliver defensible value-add services that augment their existing products. We believe that lab directors only have a few years to decide how to react to the impending waves of innovation incrementally disrupting their industry. The market is struggling under increased commoditization, lowering margins and tightening regulations. Through innovation we help labs build an attractive and integral service offering," explained Dr Baher.

Today Medicus is focused on scalable distribution strategies in existing and new markets from its Vienna headquarters, with offices in Berlin, Paris and Beirut. In late 2018, Medicus signed a market access cooperation with Roche Diagnostics, which will amplify its global reach.

"Medicus is working towards transforming the healthcare sector, simplifying the relations between providers and patients, and leading to better health outcomes," concluded Dr Baher. "Our growing global knowledge and partnerships will help us achieve these outcomes."

For further information, please visit:
http://www.medicus.ai

About Medicus

Medicus is an AI-based platform that converts health data into an interactive experience with easy-to-understand explanations, personalized health insights and smart wellbeing coaching.

Medicus is used by diagnostic labs and health insurance companies to provide patient-friendly health reports and foster continuous and personalized wellbeing coaching.

Medicus is based in Vienna, with offices in Berlin, Paris and Beirut.

Most Popular Now

What the Radiologist should Know about A…

This paper aims to provide a review of the basis for application of AI in radiology, to discuss the immediate ethical and professional impact in radiology, and to consider possible...

The Mobile Game that can Detect Alzheime…

A specially designed mobile phone game can detect people at risk of Alzheimer's - according to new research from the University of East Anglia. Researchers studied gaming data from an...

Hospital Diagnoses Critically Ill Childr…

The Rady Children’s Hospital (San Diego, USA) used Moon, software developed by the Leuven-based (Belgium) company Diploid. Moon is the first software worldwide to use Artificial Intelligence (AI) for the...

AstraZeneca Starts Artificial Intelligen…

AstraZeneca and BenevolentAI began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic...

Novartis Presents First-of-its-Kind Algo…

Novartis today announced results from a validation study of the innovative, algorithm-based digital solution MS Progression Discussion Tool, or MSProDiscussTM. The tool aims to support and facilitate a discussion between...

Bayer Joins Sensyne Health Consortium Wo…

Sensyne Health plc (LSE: SENS), the British clinical AI technology company, and Bayer, the life sciences company, announce that Bayer has become Sensyne Health's preferred pharmaceutical partner to work together...

Red Hat Helps Public Health England Use …

Red Hat, Inc. (NYSE: RHT), the world's leading provider of open source solutions, announced that Public Health England (PHE), an executive agency of the Department of Health and Social Care...

Chipmunk Health Chooses Philips HealthSu…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced that telehealth service provider Chipmunk Health, with locations in the Netherlands and Canada, is leveraging the capabilities...

Siemens Healthineers and European Societ…

With their first course under the heading "Intelligence. Innovation. Imaging - The perfect vision of AI," held in Barcelona on April 5-6, Siemens Healthineers and the European Society of Radiology...

Mobile Prenatal App Shown to Reduce in-P…

Using the mobile app Babyscripts reduced in-person prenatal care visits while maintaining patient and provider satisfaction, according to research published in JMIR mHealth and uHealth by physician researchers from the...